Member Info for RayPointer

You are correct Cleaner.
No mention of the 3 trials for instance and no mention of the platforms.

The original collaboration was aimed at TCR therapy, but Lindy did say at the AGM that Biontech were interested in Modi1 the vaccine.
Why would they not be interested. Lindy has also said in the past that Ugur Sahin is intrigued by Moditope.

Hi Chester
Didn't Lindy say at the AGM that iSCIB1+ is ready but Scancell have to negotiate with the MHRA with a view to including it in the trail sometime in 2023.

What a great problem to have for Lindy.
I am so pleased for her after such a long and dedicated career.

My Ass Toot hero :-)

It's very suspicious that Rats bought just before the latest Trish news :-)

This is an interesting recent article on Autophagy

https://www.nature.com/articles/s41418-019-0474-7

The article is mainly concerned with how to inhibit Autophagy at the 5 different stages the process goes through.
Here is part of the summary at the end:

"The real question is not whether we should or should not target autophagy. Instead, we should focus on how to do so in a way that will maximize the benefit. This could include improved drugs to manipulate autophagy and improved clinical trial design and patient selection. By understanding the molecular mechanisms by which autophagy elicits its effects on tumor behavior and combining this knowledge with a better understanding of how our deliberate interventions to target the pathway actually work, it may be possible to build on the examples described above and develop rationally based interventions to control and manipulate this process to improve treatment."

Lindy, in contrast, realises that autophagy leads to a stress induced post-translational modification called citrullination and she and her team have designed Modi1 to target citrullinated proteins (or rather epitopes).
This is an entirely different approach that does not seek to restrict Autophagy but rather encourage it since it provides the ubiquitous targets required by Modi1.

https://www.researchgate.net/publication/356063197_Citrullinated_Epitopes_Identified_on_Tumour_MHC_Class_II_by_Peptide_Elution_Stimulate_Both_Regulatory_and_Th1_Responses_and_Require_Careful_Selection_for_Optimal_Anti-Tumour_Responses

Modi1 is unique because Scancell have cornered the market on citrullinated epitopes as targets for cancer via patents.

It is worth a quick reminder of the members of the grand challenge team who were to support Lindy in developing Modi3.

1. Project Blueprint Team
Prof LG Durrant University of Nottingham Scancell Ltd., Nottingham
Prof Sahin TRON, Mainz BioNTech, Mainz
Prof Melief University of Leiden ISA pharmaceuticals, Leiden
Prof Mellman Genentech, South San Francisco
Prof Cerundulo University of Oxford
Prof Balachandran Memorial Sloan Kettering Cancer Center, New York Icahn School of Medicine at Mount Sinai, New York
Prof de Vries Radboud University, Nijmegen
Prof Platten German Cancer Research Center, Heidelberg
University Hospital Mannheim Heidelberg University
Prof Rammensee Eberhard-Karls University Tuebingen
Dr Benham University of Durham
Prof Ottensmeier University of Southampton
Prof Jaeger National Center for Tumor Diseases University Medical Center Heidelberg German Cancer Research Center, Heidelberg
Prof Pandurangan La Jolla Institute for Allergy & Immunology
Prof Mehanna University of Birmingham

That team, more than anything else IMO, gives credence to the notion that Moditope is potentially very special indeed.

I am a football fan, but I do agree with Rats that Moditope is more interesting.

I agree VanVan, we should all be eagerly awaiting the promised update before year end.

"The Company expects further safety and immunogenicity data to be available in H2 2022 and early efficacy data in 2023."

Morning all
A good day yesterday with a return to argumentative posts. Maybe Friday night fight is on the cards today.
The CD4 TCELLS also found it good fun.

Let's examine the facts

Safety is not an issue
One patient has a reduced tumour by at least 30 percent
It looks very much like for 2 other patients the T Cells are starting to do their work
Recruitment is going incredibly well
Lindy is very excited

Obviously small numbers at the moment so the results are nowhere near being statistically significant (balance must always be maintained)

Lastly, Germany are out of the world Cup :-)

or when the SP hits £80 :-)

Yes, thanks JB
And recruitment is now going so well in the monotherapy cohorts.
So, there will come a point in the not-too-distant future where accumulation of initial data will accelerate.

I like crumbs reply much better than mine :-)

"What I mean is what are likely sequence of events here?"

Who knows, there are obviously different scenarios opening up.
If initial results prove to "exceed our best expectations" as with the SCIB1 trial, then Scancell could very well get approaches from interested parties.
The question would then be whether Lindy would consider a deal at an early stage of the trial. We know there will be interest from the members of the Grand Challenge but also Scancell have said in the past that they have received unsolicited enquiries about Moditope.

It's a case of "watch this space"

But just imagine the media furore if Modi1 is proved to eradicate tumours for hard to treat cancers.
All talk will be about RSI - Rocket Sustainability Indicator

"Can it be added to other covid vaccines to “ boost “ their effectiveness?"

Lindy has stated in the past the Avidimab could possibly be added to any existing mAb.
She has also obviously managed to add it to any Immunobody vaccine.
As far as we know, there are no current plans to add it to any other type of vaccine

Another day of those amazing cells doing damage to tumours

There will always be traders keen to take profits after the recent great run.
A few take profits and others follow I suspect.

The CD4+ cytotoxic TCells are disappointed with the SP so far today but they have promised not to go on strike :-)

Konar, I was wondering if the same or similar safety cautions are applied to the expansion cohorts as were applied to cohorts 1 and 2. Alternatively, they may just be allowed to go full steam ahead since there were no safety concerns in cohorts 1 and 2.
Regardless of this, I should think there will frequent updates since it's almost like 4 trials in 1 from now on.

Thanks Bermuda
From memory I think Lindy said about 6 weeks to analyse and publish the results.